Simcha Therapeutics Raises $40M in Series B Funding
- Simcha Therapeutics, a New Haven, Ct.-based biotechnology company developing cytokine-based cancer immunotherapies, raised $40m in Series B funding
- The round was led by SR One Capital Management with participation from BVF Partners, Samsara BioCapital, Rock Springs Capital, ArrowMark Partners, and Logos Capital
- In conjunction with the financing, Simeon George, MD, Chief Executive Officer of SR One Capital Management, has joined the SimchaTherapeutics Board of Directors
- The company intends to use the funds to continue to expand its development efforts initiating Phase 1/2 Study to evaluate novel Interleukin-18 variant in cancer
- Founded in 2018 by Aaron Ring, MD, PhD, Assistant Professor of Immunobiology at the Yale School of Medicine
- SimchaTherapeutics uses directed evolution to engineer novel cytokines designed to unlock the immune system
